MAYO CLINIC
Q4 2020 Form 13-F
ROCHESTER, MINNESOTA
CIK 0001318153
· Institutional investment manager
$83.1M Reported Value Total
Reported value
$83.1M
Quarter over quarter
+29.4%
Holdings
9
Top-10 concentration
100.0%
Key People
Named on the latest Form 13-F filing — not necessarily an owner
Paul A Gorman
Chief Investment Officer
Filing Navigation
13F Metrics
Loading 13F Metrics
Q4 2020 13F record
Q4 2020 13F filing summary
| Period of report | December 31, 2020 |
|---|---|
| Filed | February 11, 2021 |
| Form | 13F-HR |
| Reported value | $83.1M |
| Positions | 9 |
| Change in reported value | +12.0% |
| New positions | 1 |
| Exited positions | 1 |
| Position turnover | 20.0% |
| Top-10 concentration | 100.0% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q3 2024 13F
Filed Nov 12, 2024
|
3 | $2.9M |
|
Q2 2024 13F
Filed Aug 12, 2024
|
4 | $3.0M |
|
Q1 2024 13F
Filed May 13, 2024
|
5 | $6.1M |
|
Q4 2023 13F
Filed Feb 13, 2024
|
7 | $16.2M |
|
Q3 2023 13F
Filed Nov 14, 2023
|
9 | $51.9M |
|
Q2 2023 13F
Filed Aug 9, 2023
|
11 | $97.4M |
|
Q1 2023 13F
Filed May 5, 2023
|
13 | $121.8M |
|
Q4 2022 13F
Filed Jan 26, 2023
|
13 | $188.8M |
|
Q2 2021 13F
Filed Aug 12, 2021
|
9 | $90.4M |
|
Q1 2021 13F
Filed May 13, 2021
|
8 | $86.9M |
|
Q4 2020 13F
Filed Feb 11, 2021
|
9 | $83.1M |
|
Q3 2020 13F
Filed Nov 12, 2020
|
9 | $74.2M |
|
Q2 2020 13F
Filed Aug 13, 2020
|
8 | $104.5M |
|
Q1 2020 13F
Filed Apr 24, 2020
|
7 | $39.5M |
|
Q4 2019 13F
Filed Feb 12, 2020
|
8 | $88.2M |
Top 9 holdings · Q4 2020
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | BSM Black Stone Minerals | $38.2M | 45.97% |
| 2 | ZNTL Zentalis Pharmaceuticals Inc | $18.8M | 22.65% |
| 3 | UBX Unity Biotechnology Inc | $8.2M | 9.91% |
| 4 | SPY SPDR ETF | $6.2M | 7.43% |
| 5 | EVLO Evelo Bioseciences Inc | $5.9M | 7.05% |
| 6 | SRNEQ Sorento Therapeutics | $4.5M | 5.41% |
| 7 | CLPT Clearpoint Neuro Inc (fka MRI INTERVENTIONS INC) | $749.0K | 0.9% |
| 8 | BSGM Biosig Tech Inc | $393.0K | 0.47% |
| 9 | EXAS Exact Sciences Corp | $173.0K | 0.21% |
Values as reported on the Q4 2020 Form 13F. Every position is in the holdings table below.